Oppenheimer Starts Cleveland BioLabs (CBLI) at Outperform
Tweet
Share
E-mailGet Alerts CBLI Hot Sheet
Price: $3.17 --0%
Rating Summary:
2 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 10 | New: 14
Rating Summary:
2 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 10 | New: 14
Join SI Premium – FREE
Oppenheimer initiates coverage on Cleveland BioLabs (NASDAQ: CBLI) with a Outperform. PT $3.00.
The firm comments, "Cleveland BioLabs is a development stage biotechnology company pursuing a broad pipeline of assets. The company's leading drug is Entolimod, which modulates apoptosis (natural cell death). This mechanism has a range of potential applications, including protecting healthy cells after injury such as radiation or oxygen deprivation, as well as a direct anti-tumor agent. Entolimod's most advanced indication is in biodefense as a therapeutic protectant following radiation exposure. The company is commencing pivotal studies, and we anticipate a BLA filing in 4Q14. Entolimod appears to be well differentiated in the biodefense application, with a significant barrier to entry for competitors."
For an analyst ratings summary and ratings history on Cleveland BioLabs click here. For more ratings news on Cleveland BioLabs click here.
Shares of Cleveland BioLabs closed at $1.40 yesterday.
The firm comments, "Cleveland BioLabs is a development stage biotechnology company pursuing a broad pipeline of assets. The company's leading drug is Entolimod, which modulates apoptosis (natural cell death). This mechanism has a range of potential applications, including protecting healthy cells after injury such as radiation or oxygen deprivation, as well as a direct anti-tumor agent. Entolimod's most advanced indication is in biodefense as a therapeutic protectant following radiation exposure. The company is commencing pivotal studies, and we anticipate a BLA filing in 4Q14. Entolimod appears to be well differentiated in the biodefense application, with a significant barrier to entry for competitors."
For an analyst ratings summary and ratings history on Cleveland BioLabs click here. For more ratings news on Cleveland BioLabs click here.
Shares of Cleveland BioLabs closed at $1.40 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
- KeyBanc Starts Super Micro Computer (SMCI) at Sector Weight, 'shares currently trading relatively inline with its infrastructure peer group'
- CLSA Starts Yokohama Rubber Co (5101:JP) at Underperform (4)
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
